ISMPP Highlights
ISMPP Authorship Algorithm Tool – Ready to Use!
It’s Here! ISMPP is thrilled to announce the release of its Authorship Algorithm Tool, a web-based tool designed to help you better determine contributions to criterion 1 for authorship based on the ICMJE Recommendations. The Tool is available FREE to COMPANIES, with an ISMPP member serving as the Company Admin…
Future-Ready & In-Person at the 18th Annual Meeting!
ISMPP is thrilled to report that 595 attendees gathered at the 18th Annual Meeting of ISMPP, May 9-11, 2022, in Washington, DC – a celebrated attendance for our first in-person Annual Meeting since 2019! We were also honored that 247, over 40%, were first-time attendees to an ISMPP Annual Meeting! This article shares highlights and photos from the 18th Annual Meeting…
Author Selection Practices Recommended by ISMPP Authorship Task Force – Now Published in CMRO
Author selection based on ICMJE criterion 1 can be challenging, particularly for multicenter trials with a large number of investigators and contributors. The ISMPP Authorship Task Force was formally launched in 2019 to define author selection best practices for industry-sponsored medical publications. The recommendations were published in CMRO on April 19, 2022…
Message from Our Leadership
Robert J. Matheis
ISMPP President and CEO
News and Trends
The Public Face of Science: Elevating Trust through Medical Communications – Continuing the Conversation
In any relationship, whether business or personal, transparency breeds trust. Today, despite the life science industry delivering unprecedented vaccine solutions to address the Covid pandemic, mistrust remains engrained in the public persona. Third parties have leveraged that doubt for their own gain…
A Snapshot into Medical Affairs
What does a Medical Affairs team look like at a pharmaceutical/biotechnology company? Is it like a bag of M&M’S® with similar functions, or is it unique from company to company, like a fingerprint? We conducted a survey of ISMPP members in March 2021, that provides insights into what comprises Medical Affairs at pharmaceutical/biotechnology companies…
A Company’s Approach to Developing Publication Plain Language Summaries
Scientific publications tend to be written with a specialized audience in mind… Plain language summaries (PLS) of publications represent a way to communicate research more broadly using everyday language. Pfizer recognized this, and in early 2020 implemented a company-wide process for developing PLS…
What Would You Do?
In our role as medical publication professionals, we may occasionally encounter situations in which it is not obvious how to ensure good publication practice. Have you ever wished you could consult the ISMPP membership for guidance when these situations arise? Here’s your opportunity!
What Would You Do? is a section of The MAP that presents case scenarios as an educational tool for medical publication professionals. The section provides a case scenario to ponder, and readers are invited to participate in a poll by selecting one of the listed solutions. Readers can also submit their thoughts on the scenario anonymously. The poll results, plus educational insights, are posted in a later issue for readers to digest.
POLL RESULTS: Journal Questions Medical Writer Acknowledgement & Funding
The lead author of a meta-analysis manuscript received a rejection notice from a journal that stated “…although the topic may be of interest to the readership, the Editors are concerned about the perception of bias given the statement of funding support from the sponsor and the participation of a paid, professional medical writer.” The lead author has emailed all authors, sponsor, and medical communications agency suggesting that the manuscript be revised by the authors alone so that acknowledgement of the medical writer and funding from the sponsor to support medical writing can be removed…
ISMPP (pronounced IzMap) is the only nonprofit organization founded by medical publication professionals for medical publication professionals